REGENCELL BIOSCIENCE HOLDINGS LIMITED UNDERWRITING AGREEMENTUnderwriting Agreement • June 11th, 2021 • Regencell Bioscience Holdings LTD • Medicinal chemicals & botanical products • New York
Contract Type FiledJune 11th, 2021 Company Industry JurisdictionThe undersigned, Regencell Bioscience Holdings Limited, a corporation incorporated under the laws of the Cayman Islands (the “Company”), hereby confirms its agreement (this “Agreement”) to issue and sell to the underwriter or underwriters, as the case may be, named in Schedule I hereto (each, an “Underwriter” and, collectively, the “Underwriters;”), for whom Maxim Group LLC is acting as representative (in such capacity, the “Representative”), (A) an aggregate of __________ ordinary shares (the “Firm Shares”) par value $0.00001 per share of the Company (“Ordinary Shares”) and (B) at the election of the Representative, (i) up to an additional _______ Ordinary Shares (the “Option Shares”, and together with the Firm Shares, the “Shares”). The offering and sale of the Shares contemplated by this Agreement is referred to herein as the “Offering”.
AGREEMENT OF OPTION TO PURCHASE ORDINARY SHARE OF Regencell Bioscience Holdings Limited (the “COmpany”)Agreement • June 11th, 2021 • Regencell Bioscience Holdings LTD • Medicinal chemicals & botanical products • New York
Contract Type FiledJune 11th, 2021 Company Industry JurisdictionWHEREAS, the Company has approved 2021 Share Option Plan on May 31, 2021, pursuant to which the Chief Executive Officer (“CEO”) of the Company may grant options to consultants, employees, and directors (collectively, “Service Provider”) of the Company with the approval of the Board of Directors (the “Board”);